TGTX
TG THERAPEUTICS, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $20 | $39 | +98% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $21 | $39 | +89% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $21 | $39 | +89% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $21 | $39 | +89% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $21 | $39 | +89% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $21 | $39 | +89% |
| Bridgewater Associates | Q4 2025 | 2Q | $31 | $39 | +28% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management 2× in & out | Q3 2025 | Q2 2026 | → $40 | +42% |
| Duquesne Family Office | Q2 2024 | Q3 2024 | → $21 | +18% |
| Maverick Capital | Q3 2020 | Q2 2023 | → $31 | +45% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at TG THERAPEUTICS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jan 29, 2026 — the most recent Form 4 on file — not from today.
- Form 40001437749-26-002439Jan 29, 2026
- Form 40001437749-26-001016Jan 9, 2026
- Form 40001437749-26-001015Jan 9, 2026
- Form 40001437749-25-036358Nov 25, 2025
- Form 40001437749-25-033888Nov 7, 2025
- Form 40001437749-25-028952Sep 12, 2025
- Form 40001437749-25-020546Jun 16, 2025
- Form 40001437749-25-020545Jun 16, 2025
- Form 40001437749-25-020543Jun 16, 2025
- Form 40001437749-25-020541Jun 16, 2025
- Form 40001437749-25-020540Jun 16, 2025
- Form 40001437749-25-008284Mar 18, 2025
- Form 40001437749-25-007052Mar 11, 2025
- Form 40001437749-25-002292Jan 30, 2025
- Form 40001437749-25-002290Jan 30, 2025
Fundamentals
XBRL · TG THERAPEUTICS, INC.Annual figures sourced directly from TG THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for TG THERAPEUTICS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KFORM 8-KJun 3, 2026
- 8-KFORM 8-KMay 27, 2026
- 10-QFORM 10-QMay 6, 2026
- 8-KFORM 8-KMay 6, 2026
- DEF 14AFORM DEF 14AApr 30, 2026
- 8-KFORM 8-KMar 20, 2026
- 10-KFORM 10-KFeb 27, 2026
- 8-KFORM 8-KFeb 26, 2026
- 8-KFORM 8-KJan 13, 2026
- 10-QFORM 10-QNov 5, 2025
- 8-KFORM 8-KNov 3, 2025
- 10-QFORM 10-QAug 8, 2025
- 8-KFORM 8-KAug 4, 2025
- 8-KFORM 8-KJun 13, 2025
- 10-QFORM 10-QMay 9, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Renaissance Technologies | Q2 2026 | open | $41 | $39 | -3% |
| Bridgewater Associates | Q4 2025 | open | $31 | $37 | +18% |
| Point72 Asset Management | Q3 2025 | Q2 2026 | $28 | $40 | +42% |
| Millennium Management | Q2 2025 | open | $34 | $39 | +18% |
| Renaissance Technologies | Q2 2025 | Q3 2025 | $33 | $28 | -17% |
| Citadel Advisors | Q3 2024 | open | $21 | $39 | +89% |
| Two Sigma Investments | Q3 2024 | open | $21 | $39 | +89% |
| D.E. Shaw | Q3 2024 | open | $21 | $39 | +89% |
| AQR Capital Management | Q3 2024 | open | $21 | $39 | +89% |
| Millennium Management | Q3 2024 | Q1 2025 | $21 | $31 | +47% |
| Point72 Asset Management | Q3 2024 | Q4 2024 | $21 | $31 | +48% |
| Renaissance Technologies | Q3 2024 | Q4 2024 | $20 | $35 | +75% |
| Duquesne Family Office | Q2 2024 | Q3 2024 | $18 | $21 | +18% |
| Maverick Capital | Q3 2020 | Q2 2023 | $22 | $31 | +45% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.